公开(公告)号：US11993820B2

公开(公告)日：2024-05-28

申请号：US17234297

申请日：2021-04-19

Applicant: Quest Diagnostics Investments LLC

Inventor： Kevin Qu ,  Feras Hantash ,  Amber Donahue

IPC: C12Q1/6886 ,  C07K14/82 ,  C12N9/16 ,  C12Q1/6816 ,  C12Q1/6827

CPC classification number: C12Q1/6886 ,  C07K14/82 ,  C12N9/16 ,  C12Q1/6816 ,  C12Q1/6827 ,  C12Q2600/112 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/16

Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.

公开(公告)号：US20210254172A1

公开(公告)日：2021-08-19

申请号：US17234297

申请日：2021-04-19

Applicant: Quest Diagnostics Investments LLC

Inventor： Kevin Qu ,  Feras Hantash ,  Amber Donahue

IPC: C12Q1/6886 ,  C12N9/16 ,  C07K14/82 ,  C12Q1/6816 ,  C12Q1/6827

Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.

公开(公告)号：US20190177805A1

公开(公告)日：2019-06-13

申请号：US16324365

申请日：2017-08-09

Applicant: Quest Diagnostics Investments LLC

Inventor： Kevin Qu ,  Feras Hantash ,  Amber Donahue

IPC: C12Q1/6886 ,  C12Q1/6827 ,  C12Q1/6816

Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.

公开(公告)号：US20240301508A1

公开(公告)日：2024-09-12

申请号：US18674280

申请日：2024-05-24

Applicant: Quest Diagnostics Investments LLC

Inventor： Kevin Qu ,  Feras Hantash ,  Amber Donahue

IPC: C12Q1/6886 ,  C07K14/82 ,  C12N9/16 ,  C12Q1/6816 ,  C12Q1/6827

CPC classification number: C12Q1/6886 ,  C07K14/82 ,  C12N9/16 ,  C12Q1/6816 ,  C12Q1/6827 ,  C12Q2600/112 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/16

Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.

公开(公告)号：US10982288B2

公开(公告)日：2021-04-20

申请号：US16324365

申请日：2017-08-09

Applicant: Quest Diagnostics Investments LLC

Inventor： Kevin Qu ,  Feras Hantash ,  Amber Donahue

IPC: C12Q1/6886 ,  C12N9/16 ,  C07K14/82 ,  C12Q1/6816 ,  C12Q1/6827

Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.